Research ExplorerPublicationsNCALD as a potential predictive biomarker for the efficacy o...

NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer

Standard

NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer. / Konrad, Sarah M; Schwamborn, Kristina; Krüger, Achim; Honert, Katja; Schmitt, Manfred; Hellmann, Daniela; Schmalfeldt, Barbara; Meindl, Alfons; Kiechle, Marion; Quante, Anne S; Brambs, Christine; Grill, Sabine; Ramser, Juliane.

In: BIOMARK MED, Vol. 16, No. 14, 10.2022, p. 1029-1041.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Konrad, SM, Schwamborn, K, Krüger, A, Honert, K, Schmitt, M, Hellmann, D, Schmalfeldt, B, Meindl, A, Kiechle, M, Quante, AS, Brambs, C, Grill, S & Ramser, J 2022, 'NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer', BIOMARK MED, vol. 16, no. 14, pp. 1029-1041. https://doi.org/10.2217/bmm-2021-0781

APA

Konrad, S. M., Schwamborn, K., Krüger, A., Honert, K., Schmitt, M., Hellmann, D., Schmalfeldt, B., Meindl, A., Kiechle, M., Quante, A. S., Brambs, C., Grill, S., & Ramser, J. (2022). NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer. BIOMARK MED, 16(14), 1029-1041. https://doi.org/10.2217/bmm-2021-0781

Vancouver

Konrad SM, Schwamborn K, Krüger A, Honert K, Schmitt M, Hellmann D et al. NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer. BIOMARK MED. 2022 Oct;16(14):1029-1041. https://doi.org/10.2217/bmm-2021-0781

Bibtex

@article{377d4a1c767547f9bf7b1fc369b7c260,
title = "NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer",
abstract = "Aim: Since reliable response predictors to platinum-based chemotherapy in ovarian cancer (OC) are scarce, we characterize NCALD as a predictive biomarker. Materials & methods: NCALD mRNA (n = 100) and protein (n = 102) expression was analyzed in OC samples and associated with patient outcome. A stable OC cell line knockdown was generated and cellular response to platinum was explored. Results: High NCALD mRNA and protein expression was significantly associated with longer overall patient survival (p = 0.037/0.002). Knockdown experiments revealed a significant association between cisplatin sensitivity and NCALD expression. Conclusion: Low NCALD expression was associated with reduced sensitivity to platinum-based chemotherapy. NCALD may be a new biomarker candidate to identify patients who might benefit from platinum-based chemotherapy.",
keywords = "Humans, Female, Platinum/therapeutic use, Prognosis, Ovarian Neoplasms/drug therapy, Cisplatin/therapeutic use, Biomarkers, Drug Resistance, Neoplasm/genetics, Neurocalcin/genetics",
author = "Konrad, {Sarah M} and Kristina Schwamborn and Achim Kr{\"u}ger and Katja Honert and Manfred Schmitt and Daniela Hellmann and Barbara Schmalfeldt and Alfons Meindl and Marion Kiechle and Quante, {Anne S} and Christine Brambs and Sabine Grill and Juliane Ramser",
year = "2022",
month = oct,
doi = "10.2217/bmm-2021-0781",
language = "English",
volume = "16",
pages = "1029--1041",
journal = "BIOMARK MED",
issn = "1752-0363",
publisher = "Future Medicine Ltd",
number = "14",

}

RIS

TY - JOUR

T1 - NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer

AU - Konrad, Sarah M

AU - Schwamborn, Kristina

AU - Krüger, Achim

AU - Honert, Katja

AU - Schmitt, Manfred

AU - Hellmann, Daniela

AU - Schmalfeldt, Barbara

AU - Meindl, Alfons

AU - Kiechle, Marion

AU - Quante, Anne S

AU - Brambs, Christine

AU - Grill, Sabine

AU - Ramser, Juliane

PY - 2022/10

Y1 - 2022/10

N2 - Aim: Since reliable response predictors to platinum-based chemotherapy in ovarian cancer (OC) are scarce, we characterize NCALD as a predictive biomarker. Materials & methods: NCALD mRNA (n = 100) and protein (n = 102) expression was analyzed in OC samples and associated with patient outcome. A stable OC cell line knockdown was generated and cellular response to platinum was explored. Results: High NCALD mRNA and protein expression was significantly associated with longer overall patient survival (p = 0.037/0.002). Knockdown experiments revealed a significant association between cisplatin sensitivity and NCALD expression. Conclusion: Low NCALD expression was associated with reduced sensitivity to platinum-based chemotherapy. NCALD may be a new biomarker candidate to identify patients who might benefit from platinum-based chemotherapy.

AB - Aim: Since reliable response predictors to platinum-based chemotherapy in ovarian cancer (OC) are scarce, we characterize NCALD as a predictive biomarker. Materials & methods: NCALD mRNA (n = 100) and protein (n = 102) expression was analyzed in OC samples and associated with patient outcome. A stable OC cell line knockdown was generated and cellular response to platinum was explored. Results: High NCALD mRNA and protein expression was significantly associated with longer overall patient survival (p = 0.037/0.002). Knockdown experiments revealed a significant association between cisplatin sensitivity and NCALD expression. Conclusion: Low NCALD expression was associated with reduced sensitivity to platinum-based chemotherapy. NCALD may be a new biomarker candidate to identify patients who might benefit from platinum-based chemotherapy.

KW - Humans

KW - Female

KW - Platinum/therapeutic use

KW - Prognosis

KW - Ovarian Neoplasms/drug therapy

KW - Cisplatin/therapeutic use

KW - Biomarkers

KW - Drug Resistance, Neoplasm/genetics

KW - Neurocalcin/genetics

U2 - 10.2217/bmm-2021-0781

DO - 10.2217/bmm-2021-0781

M3 - SCORING: Journal article

C2 - 36444691

VL - 16

SP - 1029

EP - 1041

JO - BIOMARK MED

JF - BIOMARK MED

SN - 1752-0363

IS - 14

ER -